Analysts think ALT stock price could increase by 286%
Aug 01, 2024, 6:26 AM
5.51%
What does ALT do
Altimmune, Inc., a clinical stage biopharmaceutical company based in Gaithersburg, Maryland, focuses on developing peptide-based treatments for obesity and liver diseases and has subsidiaries globally. Its leading products, pemvidutide and HepTcell, are undergoing Phase II clinical trials in multiple countries for various indications.
8 analysts think ALT stock price will increase by 285.51%. The current median analyst target is $24.48 compared to a current stock price of $6.35. The lowest analysts target is $10.10 and the highest analyst target is $29.40.
📡️ Health Care
Price Target
More Signals
Feature in Progress
This section is under development. Check back soon for updates!
